national survey on pathology laboratories showed a wide variation of specimen types in both the exempt (two to 40) and the gross-only category (six to 57). 12 Evidently, surgeons and pathologists did not share a consensus on what qualifies as productive examination.
Lesions of the upper extremity are common, with an estimated 15 percent of all soft-tissue tumors found in the human body localized to the hand. 13, 14 Among all benign upper extremity tumors, ganglions are noted to be the most prevalent (50 to 70 percent), followed by giant cell tumors of the tendon sheath (14 percent), and mucous cysts (11 percent) . 15 The risk of an upper extremity lesion being malignant is very low at 1 to 2 percent 16, 17 for both soft-tissue tumors 18 and bony tumors. 19 Several authors have stated that because malignant lesions of the upper extremity are so uncommon, histopathologic tissue analysis is rarely beneficial to warrant routine examination. 20, 21 Routine pathologic evaluation of excised specimens has been questioned in many surgical fields, including plastic surgery, orthopedic surgery, urology, otolaryngology, and general surgery. [1] [2] [3] [4] 6, 7, 13, [21] [22] [23] [24] [25] [26] [27] Previous works have uniformly found that routine surgical pathologic diagnosis did not change the treatment plan and thus concluded that the practice was neither costeffective 25 nor cost-beneficial. [1] [2] [3] [4] 6, 7, 13, [21] [22] [23] [24] [25] [26] [27] In the field of hand surgery, the value of pathologic examination of benign tumors of the upper extremity has been investigated in a few case series, demonstrating minimal clinical benefit. 2, 6, 13 These studies had limited external validity, because they were restricted to a single institution or a local network of health care centers. They also submitted all of their excised specimens for pathologic evaluation. 2, 6, 13 This study design does not reflect a realistic practice pattern, because a 100 percent submission rate is highly unlikely, especially if the surgeon is not suspecting malignancy.
A wide variation already existed among institutional policies regarding specimens exempt from surgical pathology in 1999. 12 To investigate the current pattern of use of routine surgical pathologic examination in hand surgery, we designed a retrospective cohort study with cross-sectional analysis of national claims data for excision of nonmalignant lesions of the upper extremity. We hypothesize that routine examination of hand surgical specimens with little to no clinical gain is still practiced routinely. Furthermore, we demonstrate an estimate of the national expenditure on this routine practice to quantify the potential monetary saving and to guide health care policy toward improving efficiency and quality of care.
PATIENTS AND METHODS

Data Source
This study is exempt from institutional review board oversight. We investigated claims data from the Truven Health MarketScan Research Databases: the Commercial Claims and Encounters Database and the Medicare Supplement and Coordination of Benefits Database from 2009 to 2015. MarketScan Databases capture personspecific clinical use, cost, and enrollment across inpatient and outpatient services. The data come from a large selection of employers and represent medical experiences for insured employees, their dependents, and early retirees. Each claim can be connected to a specific patient through a unique identification number; a patient can be followed through multiple clinical encounters.
Inclusion Criteria
We included patients aged 18 years or older who underwent outpatient excision of nonmalignant lesions of the upper extremity between 2009 and 2015; CPT codes were used. We defined "nonmalignant lesion" as those that were not diagnosed malignant at the time of excision but were not necessarily labeled benign. For surgical CPT codes that are not specific to the upper extremity (e.g., code 11400, Excision, benign lesion, except skin tag, trunk, arms or legs; lesion diameter 0.5 cm or less), we included only claims that had an 
Exclusion Criteria
We excluded patients who underwent excision of malignant lesions of the upper extremity within 2 months before surgery; the excision may be for the purpose of assessing margins, and if so, pathologic examination is necessary. We also excluded biopsy procedures, as the purpose of the surgery is to produce a specimen for a pathologic evaluation for a definitive diagnosis to guide treatment. 15 
Independent and Dependent Variables
The outcomes of interest were the rate of specimen submission for excision of nonmalignant hand lesions and the cost of this routine practice during the 5 years between 2010 and 2015. The independent variables in this study include patient age in groups (18 to 34 years, 35 to 44 years, 45 to 54 years, 55 to 64 years, and 65 years and older), sex, median household income within the metropolitan statistical area where the patient resided, insurance plan type, and geographic region where the surgery took place. We calculated a comorbidity score for each patient using the modified Elixhauser comorbidity measures, a condensed version of the comorbidity system shown to be superior to the widely used Charlson comorbidity system.
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Statistical Analysis
We calculated the rate of specimen submission for pathologic evaluation per surgical procedure and diagnosis, and then performed a univariate analysis for the correlation between specimen submission and each patient characteristic. We examined the patient characteristics that influenced surgical pathology submission with a multivariable logistic regression model. We reported adjusted odds ratios of getting specimens submitted for each patient characteristic and the corresponding confidence intervals. We calculated the risk of malignancy revealed by routine pathologic examination by capturing the number of patients who had a new diagnosis of malignancy localized to the upper extremity dated after the initial surgery.
Then, we found the number of patients who either underwent a second excision of a malignant upper extremity lesion within 2 months from the initial procedure or received chemotherapy or radiation therapy (see Appendix B, Supplemental Digital Content 2, chemotherapy procedures and radiation procedures, http://links.lww.com/PRS/C874). We inferred that a reexcision would indicate that the original lesion was found to be malignant by pathologic evaluation, because it is unusual to excise another benign-appearing lesion separately within 2 months' time. We also examined patient characteristics to find any that were significantly correlated with malignant diagnosis by calculating odds ratios in another multivariable logistic regression model. Lastly, we determined the national total and mean cost of pathologic examination per each pathology procedure during the observed period. (See Appendix C, Supplemental Digital Content 3, for pathologic procedure CPT codes and descriptions, http://links.lww.com/PRS/C875.)
RESULTS
Sample Characteristics
The final study cohort analyzed 222,947 patients who underwent excision of benign upper extremity lesions. We found that 182,962 specimens from 153,518 cases were submitted for pathologic evaluation, resulting in an overall submission rate of 69 percent. (See Appendix D, Supplemental Digital Content 4, which shows the rate of specimen submission per surgical procedure, http://links.lww.com/PRS/C876.) There were no significant associations between specimen submission and sex, median household income, or insurance type (Table 1 ). The odds of having specimens sent for surgical pathologic evaluation decreased as the patient's age increased. For example, the odds of a patient older than 65 years getting his or her benign hand lesion submitted for pathologic evaluation was 0.64 times less compared with patients aged 18 to 34 years (Table 2 ). This trend illustrates how patient age influences treatment plans, namely, that the number of life-years potentially gained by intervention is valued less for the elderly compared with younger patients. The submission of specimens was also significantly influenced by the geographic region. Patients treated in the Northeast were most likely to have specimens submitted for pathologic evaluation (OR, 1), followed by the North Central region (OR, 0.83), the South (OR, 0.67), and lastly the West (OR, 0.50) ( Table 2 ). This may be a result of the high rate of medical litigation in the Northeast region. Lastly, patients with higher comorbidity scores were more likely to have pathologic evaluation of the specimen ( Table 2) .
Rate of Use, by Diagnosis and Surgical Procedure
In this cohort, CPT code 25111 (excision of primary wrist ganglion) was performed the most, constituting 19 percent of the total number of cases. This was closely followed by CPT code 26160 [excision of lesion of tendon sheath or joint capsule (e.g., mucous cyst, hand, or finger)] at 17 percent ( Fig. 1) Modification code 2166 (benign neoplasm of skin of upper limb, including shoulder) to be the most prevalent diagnosis, and also with the highest rate of specimen submission (87 percent). Ganglion of joint (International Classification of Diseases, Ninth Revision, Clinical Modification code 72741) was the second most prevalent diagnosis, with a rate of submission at 70 percent (Fig. 2) .
Risk of Malignancy
From 153,518 cases that had surgical pathologic evaluation, only 879 patients had a malignant diagnosis made within 2 months from the initial excision of an upper extremity lesion. Of this subgroup, 319 patients underwent a second excision of the upper extremity within 2 months of the original operation. In a discordant case, pathologic evaluation reveals new information and alters the treatment plan. In a discrepant case, the new information is revealed but does not change the treatment plan. The rate of discrepancy and discordance is calculated, with the total Plastic and Reconstructive Surgery • August 2018 number of cases undergoing pathologic evaluation as the denominator. 6, 13 Therefore, there were 319 discordant cases (0.2 percent) and 560 discrepant cases (0.4 percent) in our sample. The odds of malignant diagnosis were statistically significant for age groups 55 to 64 years (OR, 1.41) and 65 years and older (OR, 2.37), and for higher comorbidity scores (OR, 2.20 to 6.83). The odds ratios increased as the score increased (Table 3) . This indicates that a patient's high comorbidity score should alert the surgeon to a high likelihood of a malignant diagnosis.
Rate of Use and Cost: Pathologic Evaluation
A total of 182,962 pathologic examinations were captured in the analysis because pathology service is billed per specimen. The total cost of routine pathologic evaluation of nonmalignant lesions of the upper extremity during the observed 5 years was over $24 million nationally (Table 4) . On average, each specimen submitted underwent pathologic evaluation at the cost of $133 per specimen, for both technical and professional components of service. Level III gross and microscopic analysis (CPT 88304) was the most frequently performed pathologic procedure, constituting 52 percent of all pathologic procedures performed at the cost of $9.4 million (Fig. 2) . The second most used analysis was level IV gross and microscopic evaluation (CPT 88305, 36 percent); although this examination had a lower case count, the average cost was higher and thus cost more in total, at $11 million (Table 4) . Advanced histopathologic tests were rarely used (Fig. 2) . Despite the low unit cost, basic level pathologic evaluation (level I and level VI gross and microscopic analysis) has a high collective cost because it was performed frequently. Level III and level IV evaluations together constituted 88 percent of the pathology services performed on the upper extremity lesions.
DISCUSSION
There has not been a study demonstrating the nationwide pattern of practice regarding routine submission of surgical pathologic specimens for lesions of the upper extremity. Our study with a national database found that the routine pathologic evaluation of benign-appearing hand specimens has been frequently used at the rate of 69 percent. A diagnostic test is only worthwhile if the result is meaningful and provides information to guide patient care. 2 Although patients often request a definitive diagnosis of benign appearing lesions with pathology, routine pathologic evaluation is only truly beneficial if the results change the course of treatment. A few studies have examined benign hand lesions, but all of them failed to find a single discordant case. 2, 6, 13 The three studies together evaluated 714 benign hand lesions. Even if, hypothetically, lesion 715 was malignant, the cost of finding that rare case is $95,095 (715 specimens times our result of $133 per specimen). These studies concluded that the chance of ; however, in light of the nationwide initiative to contain health care costs, the value of such defensive practice must be assessed through economic analyses. Many experts have concluded that routine testing is not worthwhile. 11, 20, 21 Physicians should judiciously select the cases that warrant pathologic evaluation. We found that older age and higher comorbidity scores had higher odds of malignancy by pathology diagnosis. This does not necessarily imply that benign-appearing lesions must be sent for pathologic evaluation if the patient is older or has many comorbidities. Rather, surgeons should be hypervigilant about the likelihood of malignancy and assess the lesion for suspicious qualities and submit specimens for pathologic evaluation if concerned. The future of the health care payment model moves toward a value-based care system and bundled payments. 30 To protect adequate reimbursement and compensation for the services clinically indicated and absolutely essential, we need to reduce unnecessary components such as routine testing. 1, 30, 31 In our study, the Northeast region was associated with the highest rate of specimen submission compared with other regions. This difference is possibly attributable to the higher number of medical malpractice lawsuits in the Northeast. 32 In fact, experts suggest that more than 70 percent of the physicians across the country are influenced by the fear of medical liability. 33 There are many reasons behind repetitive and unnecessary testing, such as patient expectations, diagnostic completeness, and peer and commercial pressure. Medical malpractice management is a powerful driving force in financing health care, and fear of litigation cannot be taken lightly. [6] [7] [8] 34 The relatively low cost of individual specimen submission ($133) likely contributes to the frequent use despite the low clinical value. As individual unit cost is low, medical providers have a low decision threshold each time they order a test. 35 Thus, the simple, relatively cheap test is ordered often, with a large collective cost as a consequence. 36 In fact, a largescale systematic review found 25 to 40 percent of all laboratory tests redundant. 37 Health care in the United States is notoriously expensive, and the cost is growing at an unsustainable rate. 30, 38 The National Academy of Medicine report estimated in 2012 that $690 billion was wasted in U.S. health care annually, not including fraud. 39 According to the McKinsey Global Institute, the United States spent nearly $650 billion more than other developed countries did in 2006 after controlling for its relative wealth. 40 An analysis of the increases in health care costs over the past 30 years has revealed that two-thirds of the excess increase is caused by inefficient, repetitive testing. 7, 38, 41 The practice of defensive medicine is estimated to cost $46 billion annually in the United States, which is more than 80 percent of total expenditure for medical liability of $55.6 billion. 5 This study has several limitations. First, because of the nature of retrospective cohort analysis using diagnosis and procedure codes from a national level database, our study is biased from the inherent uncertainty and variation in coding practice and record-keeping. There is a well-known motive in the medical field to "upcode" for services; in other words, providers will preferentially select the code that will bring in higher reimbursement. In surgical fields, excision of suspicious lesions pays more than excision of benign lesions. Our result of $24 million in cost may be considered an overestimate because of the coding practice; however, our estimate still stands valid because we selected our study cohort very conservatively. The uncertain extent of upcoding is balanced by the lower number of specimens included in the analysis. Another limitation resulted from the way health care reimbursement works for health insurances, as the charges claimed by the insurance company do not precisely correlate to the actual costs incurred by the hospital or the physician. For instance, two pathologists may evaluate one surgical specimen; one physician would bill for both technical and professional components of the service, whereas the other physician may not bill at all because his or her professional service is paid by the hospital. Therefore, it is difficult to accurately determine the total cost of pathologic examination per specimen. Furthermore, the real cost of a service includes the financial expenses and other invested resources such as time, energy, and efforts of the professionals. In our study, we were able to capture only the monetary cost claimed by the insurance companies for routine pathologic evaluations. We can estimate that the real cost would be much higher. Lastly, economic analysis is constrained by the fact that the cost that society is willing to spend for a rare diagnosis has yet to be determined. Defining this price is essential for an accurate analysis of the economic value of a diagnostic test. 11 Still, considering the substantial cost of finding such a rare save, the social consensus is unlikely to deem routine testing financially justified. The concept of decreasing redundancy to improve quality is general and widely applicable to the field of plastic surgery. What we have found in our study can be extrapolated to procedures such as breast augmentation and skin grafting, that also produce similar types of specimens that are likely benign unless preoperatively suspected of being otherwise. Experts from other surgical fields such as orthopedic surgery and otolaryngology have arrived at conclusions similar to ours. [1] [2] [3] [4] 6, 7, 13, [21] [22] [23] [24] [25] [26] [27] 42, 43 We anticipate that this demonstration of the "low yield" of routine pathologic evaluation of benign hand lesions on a national level should promote a change in policy toward improving quality and efficiency of health care by guidelines to protect surgeons from practicing value-based care.
Pathologic evaluation of nonmalignant lesions of the upper extremities provides little clinical benefit yet is regularly used. Such practice costs the United States $23 million per year for solely upper extremity lesions. In efforts to contain health care costs and promote improvement in quality in accord with the national agenda for value-based care, the policy regarding routine specimen submission should be changed to decrease redundancy and increase efficiency.
